Stay updated with breaking news from Informationfor Sunlenca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Two-Year Resistance Analysis from CAPELLA Pivotal Trial Reinforces Sunlenca as a Person-Centered Option in Combination with an Optimized Background Regimen – – Latest Research Highlights...
– Long-Term & Real-World HIV Research Offer Insights into How Treatment with Biktarvy® and Sunlenca® May Help Inform the Future of Coordinated, Person-Centered HIV Care – – Updates on...
– Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety and Tolerability Profile of Lenacapavir –– Analyses Show Oral Bridging Maintains Virologic Suppression When Subcutaneous Lenacapavir Doses are Missed –FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today...
– Key Initiatives Highlight the Role of Catalytic Collaboration to Help Advance Health Equity – – Latest HIV Research and Development Data Drive the Next Wave of Person-Centric Scientific Discovery in Treatment, Prevention and Novel Research Strategies in HIV Cure –